Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Gains from Investment Securities (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Gains from Investment Securities for 8 consecutive years, with $31000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Investment Securities fell 90.0% year-over-year to $31000.0, compared with a TTM value of -$940000.0 through Sep 2025, down 1049.49%, and an annual FY2024 reading of $8.7 million, up 17.13% over the prior year.
  • Gains from Investment Securities was $31000.0 for Q3 2025 at Bicycle Therapeutics, down from $46000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $5.8 million in Q1 2023 and bottomed at -$5.2 million in Q2 2023.
  • Average Gains from Investment Securities over 5 years is $114393.7, with a median of $31000.0 recorded in 2025.
  • The sharpest move saw Gains from Investment Securities plummeted 6271.43% in 2022, then soared 16811.43% in 2023.
  • Year by year, Gains from Investment Securities stood at -$14000.0 in 2021, then tumbled by 6271.43% to -$892000.0 in 2022, then plummeted by 262.89% to -$3.2 million in 2023, then soared by 67.25% to -$1.1 million in 2024, then soared by 102.92% to $31000.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for BCYC at $31000.0 in Q3 2025, $46000.0 in Q2 2025, and $43000.0 in Q1 2025.